09:34:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMERK Equities
Vaccibody är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.


2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning VACC 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split VACC 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma
2021-05-12 08:29:00
Oslo, Norway, May 12, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, announced today the appointments of Mikkel Wandahl Pedersen as
new Chief Scientific Officer (CSO) and Agnete B. Fredriksen as Chief Innovation
& Strategy Officer.

Mikkel Wandahl Pedersen (47) has many years of experience as a scientific leader
in drug discovery with a track record of bringing drug candidates from concept
to the clinical phase. Mikkel Wandahl Pedersen comes to Vaccibody from a
position as CSO of Symphogen, a subsidiary of Servier, discovering and
developing antibody-based drugs for the treatment of cancer as well as
inflammatory and infectious diseases.

Mikkel Wandahl Pedersen, in-coming Chief Scientific Officer, says: "I am very
impressed with Vaccibody's achievements and results over the past years, both in
terms of R&D collaborations, and clinical results. On this background, I am
thrilled to join Vaccibody in these exciting times where vaccines during the
COVID-19 pandemic have truly demonstrated their critical role in the prevention
of disease. I am convinced that Vaccibody's unique platform technology and
clinical programs will make a real difference for patients in need of novel

In her role as Chief Innovation & Strategy Officer, Agnete B. Fredriksen's
responsibilities will include both the Strategy and Business Development areas.
In addition, Agnete B. Fredriksen will prioritize maintaining Vaccibody's
external scientific relations as well as the dialogue with international
specialist investors and equity analysts. Agnete B. Fredriksen have already for
several years spent a significant amount of her time in the above areas which
have grown in both significance and volume in connection with the growth of the

Agnete B. Fredriksen, Chief Innovation & Strategy Officer, says: "Since
co-founding Vaccibody in 2007, both the Company and I have been on an exciting,
fun and extremely busy journey. With Mikkel joining Vaccibody as new CSO, I look
very much forward to concentrating my energy on innovation, strategy as well as
the Company' external scientific and specialist investor relations. These are
exciting areas which have grown in importance and where I believe that I can
create the most value for Vaccibody in the next phase of our development.
Finally, I cannot wait to work very closely with Mikkel for the period to come
and ensure a successful transfer of responsibilities."
Chief Executive Officer of Vaccibody, Michael Engsig, comments: "I am extremely
pleased with the new constellation of our leadership team. This is the best of
two worlds and will further energize Vaccibody in its continued growth journey.
Both Mikkel and Agnete brings tremendous experience and excellence with them."

Mikkel Wandahl Pedersen and Agnete B. Fredriksen will commence their roles at
Vaccibody on June 1, 2021, and both will report to Michael Engsig, Chief
Executive Officer.

About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung- , head and neck, renal-, and bladder cancer